A citation-based method for searching scientific literature

Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng, Norm Rosenthal, Meg J Jardine, George Bakris, Vlado Perkovic. Circulation 2018
Times Cited: 116



Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews, Bruce Neal. Lancet Diabetes Endocrinol 2018
Times Cited: 227




List of shared articles



Times cited

A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.
Laura K Triantafylidis, Chelsea E Hawley, Christopher Fagbote, Jiahua Li, Nicole Genovese, Julie M Paik. J Pharm Pract 2021
5

SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.
Alexia Piperidou, Charalampos Loutradis, Pantelis Sarafidis. J Hum Hypertens 2021
1

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Jaime Blais, Qiang Li, Meg J Jardine,[...]. Am J Kidney Dis 2021
3

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
Jie Yu, Zien Zhou, Kenneth W Mahaffey, David R Matthews, Brendon L Neuen, Hiddo J L Heerspink, Meg J Jardine, JingWei Li, Vlado Perkovic, Bruce Neal,[...]. Int J Cardiol 2021
3

Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
Chin Meng Khoo, Chaicharn Deerochanawong, Siew Pheng Chan, Bien Matawaran, Wayne Huey-Herng Sheu, Juliana Chan, Ambrish Mithal, Andrea Luk, Ketut Suastika, Kun-Ho Yoon,[...]. Diabetes Obes Metab 2021
2

Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
James L Januzzi, Javed Butler, Naveed Sattar, Jialin Xu, Wayne Shaw, Norman Rosenthal, Michael Pfeifer, Kenneth W Mahaffey, Bruce Neal, Michael K Hansen. Diabetes Care 2021
0

Canagliflozin: metabolic, cardiovascular and renal protection.
Vivencio Barrios, Carlos Escobar. Future Cardiol 2021
1


Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
0

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Thomas A Zelniker, Itamar Raz, Ofri Mosenzon, Jamie P Dwyer, Hiddo H J L Heerspink, Avivit Cahn, Erica L Goodrich, Kyungah Im, Deepak L Bhatt, Lawrence A Leiter,[...]. JAMA Cardiol 2021
0

From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A Leiter, Antonio Ceriello, Ralph A DeFronzo, Itamar Raz. Cardiovasc Diabetol 2021
1


Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11).
Aslam Amod, John B Buse, Darren K McGuire, Thomas R Pieber, Rodica Pop-Busui, Richard E Pratley, Bernard Zinman, Marco Bo Hansen, Ting Jia, Thomas Mark,[...]. Diabetes Ther 2020
6

CREDENCE: A silver lining in the dark cloud of diabetic nephropathy.
Ko Hanai, Tetsuya Babazono. J Diabetes Investig 2020
0



Sodium-glucose linked transporter-2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk.
Guntram Schernthaner, Per-Henrik Groop, Philip A Kalra, Claudio Ronco, Maarten W Taal. Diabetes Obes Metab 2020
4




Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
David Z I Cherney, Hiddo J L Heerspink, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Zhi J Xu, Shrita Patel, Anne Hickman, James P Mancuso,[...]. Diabetologia 2020
12


Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
Christie Rampersad, Eyal Kraut, Reid H Whitlock, Paul Komenda, Vincent Woo, Claudio Rigatto, Navdeep Tangri. Am J Kidney Dis 2020
5

Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.
Megumi Oshima, Bruce Neal, Tadashi Toyama, Toshiaki Ohkuma, Qiang Li, Dick de Zeeuw, Hiddo J L Heerspink, Kenneth W Mahaffey, Gregory Fulcher, William Canovatchel,[...]. J Am Soc Nephrol 2020
1

SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies.
Mei Qiu, Liang-Liang Ding, Miao Zhang, Jin-Hao Lin, Jin-Song Gu, Xian Zhou, Ying-Xi Tang, Xu-Bin Wei, Shu-Yan Liu. Pharmacol Res 2020
4

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection.
Vikas S Sridhar, Lisa Dubrofsky, Jacinthe Boulet, David Z Cherney. J Bras Nefrol 2020
2

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.
Janani Rangaswami, Vivek Bhalla, Ian H de Boer, Alexander Staruschenko, Johanna A Sharp, Radhika Rajgopal Singh, Kevin Bryan Lo, Katherine Tuttle, Muthiah Vaduganathan, Hector Ventura,[...]. Circulation 2020
22

Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement.
Ajitesh Roy, Animesh Maiti, Anirban Sinha, Arjun Baidya, Asish Kumar Basu, Dasarathi Sarkar, Debmalya Sanyal, Dibakar Biswas, Indira Maisnam, Kaushik Pandit,[...]. Diabetes Ther 2020
4

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini. Cardiovasc Diabetol 2020
6

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
916

Preventing and treating kidney disease in patients with type 2 diabetes.
Pierre Delanaye, André J Scheen. Expert Opin Pharmacother 2019
13


New pharmacological strategies for protecting kidney function in type 2 diabetes.
Marcel H A Muskiet, David C Wheeler, Hiddo J L Heerspink. Lancet Diabetes Endocrinol 2019
27

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
73

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
Pantelis Sarafidis, Charles J Ferro, Enrique Morales, Alberto Ortiz, Jolanta Malyszko, Radovan Hojs, Khaled Khazim, Robert Ekart, Jose Valdivielso, Denis Fouque,[...]. Nephrol Dial Transplant 2019
70



An update on the safety of SGLT2 inhibitors.
André J Scheen. Expert Opin Drug Saf 2019
50

Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
Dario Giugliano, Luca De Nicola, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito. Diabetes Obes Metab 2019
20

SGLT2 inhibition to address the unmet needs in diabetic nephropathy.
Federica Barutta, Sara Bernardi, Giuseppe Gargiulo, Marilena Durazzo, Gabriella Gruden. Diabetes Metab Res Rev 2019
6



Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
224

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class.
Guntram Schernthaner, Heinz Drexel, Evgeny Moshkovich, Birute Zilaitiene, Emil Martinka, Leszek Czupryniak, Tamás Várkonyi, Andrej Janež, Kristine Ducena, Katarina Lalić,[...]. BMC Endocr Disord 2019
8